Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Search Results

Now showing 1 - 2 of 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    THE VALUE OF SERUM-ASCITES ALBUMIN GRADIENT AS A PREDICTOR OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH LIVER CIRRHOSIS AND ASCITES
    (2022-09)
    ;
    ;
    ;
    ;
    Due to the high risk of adverse outcome, identifying predisposing factors for spontaneous bacterial peritonitis (SBP) is of paramount importance. Serum ascites albumin gradient (SAAG) has recently been included in the recommendations for the management of ascites in patients with cirrhosis by some associations. ; Aim - to determine the value of SAAG as a predictor of SBP and to compare the average values of SAAG in patients with SBP and non-SBP.; The study was designed as a prospective-analytical-observational and was conducted at the University Clinic for Gastroenterohepatology in Skopje in one-year period. The study population included 70 patients hospitalized patients with established liver cirrhosis, regardless of etiology They were divided into two groups, 35 patients with SBP and 35 non-SBP, with similar demographic characteristics as the SBP group with sterile ascites, in which all variables were examined as in the study group. The selection of patients who were included in the study was conducted according to predetermined inclusion and exclusion criteria.; The average value of SAAG in SBP was 19.0±4.6, and in non-SBP it was higher (23.2±5.5). The difference between the mean values was statistically significant for p<0.05 (t-test = 3.46512; p=0.000992). The univariate analysis of SAAG in prediction of SBP showed that SAAG <20 g/L significantly increased the chance of SBP by five times (Exp (B) = 5.337 (CI (1.976-15.516)).; Our analysis registered a statistically significant difference between the average values of SAAG in both groups. SAAG is a good predictor, significantly associated with the occurrence of SBP. Additional and extensive studies are necessary in order to confirm our conclusion in the future.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Esophageal, gastric, colorectal, pancreatic, hepatocellular carcinomas and cholangiocarcinomas in Northern Macedonia: A series of patients treated at the University Clinic, between 2015 and 2019
    (Centre for Evaluation in Education and Science (CEON/CEES), 2021)
    ;
    ;
    Stefanovski, Goran
    ;
    ;
    <jats:p>Introduction: The global burden of gastrointestinal cancer (GIC) is growing. Stomach, colon and liver are among the five most common sites for GIC in men and women worldwide. The incidence of GIC shows significant variation in Europe and North America. Aim: The aim of this paper is to describe hospital morbidity from GI cancer at the University Clinic in Northern Macedonia. Materials and methods: A retrospective longitudinal analysis included a series of cases with GIC, at the University Clinic of Gastroenterohepatology (UCG) in Skopje, in the period 2015-2019. Descriptive statistical methods were used to describe hospital morbidity from GIC, and its distribution by age, sex, and cancer site. Results: In a five-year period, a total of 2,831 patients with GIC were treated at the UCG, of which 1,484 patients had colorectal cancer, 763 patients had gastric cancer and 88 patients had esophageal cancer. Although liver cancers were less common, as many as one eighth of such patients (355 or 13%) had nonspecific liver malignancy. Most patients were in the 60-69 age group, with the exception of esophageal cancer. An increase in the incidence of pancreatic cancer was observed, almost equal, when considering the distribution by sex, and mainly in the age groups 60-69 and 70-79 years. Conclusion: Hospital morbidity due to GIC in North Macedonia shows an increasing trend, so it is important to determine how much screening has contributed to the early detection of these cancers and to ensure access to and availability of therapy for hepatitis B and C.</jats:p>